Skip to main content

Uniqure

uniQure NV is a Dutch gene therapy pioneer developing adeno-associated virus (AAV) based gene therapies for severe genetic disorders. The company developed Hemgenix, the first FDA-approved gene therapy for hemophilia B, commercialized with CSL Behring, while advancing clinical programs for Huntington's disease, Fabry disease, and temporal lobe epilepsy. Principal revenues derive from commercial product sales royalties, manufacturing milestone payments, and research partnership licensing fees. Core end markets encompass specialized medical centers, hematology and neurology hospital clinics, and prescription patients across North America and Europe. uniQure holds a pioneer market-leading position in commercial-scale AAV gene therapy development and manufacturing. The company is incorporated in the Netherlands, headquartered in Amsterdam and Lexington, Massachusetts, with ordinary shares traded on the Nasdaq Global Select Market.

5 of the funds FundTelligence covers report a position in Uniqure.

Legal name
Uniqure NV
Sector
Health Care
Country
Netherlands
Funds holding it
5
Exposure themes
Gene Therapy, Genetic Medicine, Precision Medicine & Genomics

Funds holding Uniqure

Loading...